NATIONAL CANCER INSTITUTE (NCI) SMALL BUSINESS INNOVATION RESEARCH (SBIR) INNOVATIVE CONCEPT PHASE I AWARD PROGRAM

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NIH NCI

Contract Value

Not provided

Codes & Classification
Solicitation Number

75N98026R00109

NAICS

-

Classification Code

AN12

Additional Details
Set Aside

SBA

Place of Performance

UNITED STATES

SourceSAM
Documents5
The National Cancer Institute (NCI), a component of the National Institutes of Health (NIH) under the U.S. Department of Health and Human Services (HHS), has issued a solicitation for its Small Business Innovation Research (SBIR) Innovative Concept Phase I Award Program. This opportunity is specifically designed for small business concerns with the capability to conduct research and development (R&D) in health-related fields, particularly those focused on pediatric and rare cancers. The solicitation seeks to foster the development and commercialization of transformative, high-risk, high-reward technologies that have the potential to significantly impact cancer treatment, detection, and diagnosis. The scope of this procurement encompasses two primary topic areas: 1. The development of therapeutic or preventative technologies aimed at the treatment or prevention of pediatric cancers and/or rare cancers. Special emphasis is placed on rare cancers with a five-year survival rate of less than 50%. 2. The creation of devices, diagnostic technologies, or digital health tools for the treatment, detection, and diagnosis of pediatric cancers and/or rare cancers, again prioritizing those with poor survival outcomes. The intended outcome of this Phase I SBIR solicitation is to support proof-of-concept and feasibility studies for untested but potentially game-changing R&D concepts. Offerors are expected to propose projects that clearly identify the clinical problem and cancer type(s) being addressed, provide adequate scientific justification, and outline a logical development path toward an anticipated product. While preliminary data is not required, proposals must be grounded in a sound scientific premise, supported by the offeror’s own research or existing literature. The solicitation encourages experiments designed to obtain initial de-risking and proof-of-concept data. Key requirements include: - Submission of a signed copy of the SF30 Amendment (page 1 only) with the business proposal, as per the latest amendment. - Adherence to the unchanged proposal deadline of 5:00pm, September 21, 2026. - Compliance with all terms and conditions as outlined in the solicitation and subsequent amendments. - Exclusion of non-exempt human subjects research from consideration under this solicitation. The procurement is classified under Product Service Code AN12 and is set aside for small businesses in accordance with SBA guidelines. The place of performance is within the United States. The NCI’s SBIR Innovative Concept Award Program is structured as a phased initiative. Contractors awarded a Phase I Concept Award will be eligible to apply for a subsequent Phase II award; however, only one Phase II award may result from a single Phase I contract. It is important to note that HHS is not obligated to make any awards under this solicitation, and all awards are contingent upon the availability of funds. Offerors are responsible for any costs incurred prior to the award of a contract. The contracting entity for this opportunity is the NIH NCI Office. Interested parties may direct inquiries to the primary contact, Kathleen Sears, via email at [email protected]. Additional details, including amendments and attachments, are available through the official SAM.gov opportunity listing (Opportunity ID: 5ab4cf48d42c495aabef1d6cdf21acf8). This solicitation represents a significant opportunity for small businesses with innovative concepts in cancer research to secure federal support for early-stage development, with the ultimate goal of advancing new solutions for pediatric and rare cancers with critical unmet needs.